June 27, 2016 04:28 PM EDT
Pharma

Reg­u­lus craters af­ter FDA slaps a hold on hep C RNA drug fol­low­ing 2nd case of jaun­dice

John Carroll

Editor & Founder

Just days af­ter set­ting up a $30 mil­lion line of cred­it to ramp up work on its he­pati­tis C ther­a­py RG-101, Reg­u­lus Ther­a­peu­tics has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times